View links organized by who tweeted them or where they're pointing.

Some Favorite Sources: weei.com | boston.com | nytimes.com | washingtonpost.com | medium.com | theringer.com | espn.com | stonekettle.com | Current.org | niemanlab.org | hbr.org

Some Favorite Tweeters: @antrod | @benedictevans | @andrewchen | @bussgang | @cpricenfl | @techREDEF | @mediaREDEF | @sportsREDEF | @fashionREDEF | @mattermarkdaily | @jpbutler

Links Tweeted by: @biopharmadive

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 8:20 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 7:42 PM.

Apellis touts new data for eye drug hopeful
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 7:12 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 6:48 PM.

Bellicum outlines path to restart US studies of cell therapy
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 6:14 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 5:57 PM.

Apellis touts new data for eye drug hopeful
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 1:45 PM.

Oral form of Novo's Ozempic hits primary endpoint in first Phase 3
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 1:14 PM.

Bristol losing its I/O talent to the likes of Pfizer, report finds
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 12:30 PM.

Bellicum outlines path to restart US studies of cell therapy
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 23, 2018 at 12:02 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 16, 2018 at 2:20 PM.

Apricus plummets after ED drug rejection
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 16, 2018 at 12:46 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 16, 2018 at 12:16 PM.

Roche buys cancer data company Flatiron Health for $1.9B
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 16, 2018 at 11:46 AM.

DBV shares jump as peanut allergy patch heads to filing
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 6:30 PM.

Pfizer, Merck KGaA lung cancer drug fails
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 6:00 PM.

Bayer plant flagged by FDA for poor GMP practices
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 4:54 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 4:19 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 3:50 PM.

Bioverativ taps new manufacturer as it steps out of Biogen's shadow
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 3:34 PM.

DBV shares jump as peanut allergy patch heads to filing
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 1:47 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 1:07 PM.

Pfizer, Merck KGaA lung cancer drug fails
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 12:31 PM.

Biogen shares fall after unexpected 'variability' in Alzheimer's studies
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 15, 2018 at 12:04 PM.

BIO: Pain pipeline lacking as opioid crisis continues
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 7:58 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 6:00 PM.

Fresh data sets up showdown for Lilly's Taltz vs Cosentyx
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 5:30 PM.

J&J gets first-of-its-kind prostate cancer approval
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 5:06 PM.

BIO: Pain pipeline lacking as opioid crisis continues
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 2:38 PM.

Shire's pushing its growth potential, but investors aren't sold
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 2:08 PM.

Merck delivers latest Alzheimer's disappointment
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 1:42 PM.

Ramaswamy has no regrets about Axovant
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 1:10 PM.

Bristol-Myers bets $1.85B on combo potential of Nektar cancer drug
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Wednesday, Feb 14, 2018 at 12:45 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 7:59 PM.

Roivant and Poxel sign $650M diabetes deal
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 7:35 PM.

Trump pitches changes to 180-day generic exclusivity
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 7:09 PM.

Teva's Copaxone sales hit hastened with OK of Novartis copy
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 6:33 PM.

What Gilead taught pharma about pricing a cure
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 6:00 PM.

New approval helps Vertex's 'cleanest growth story in biotech'
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 5:37 PM.

Oncologie snaps up Avid's cancer assets
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 2:26 PM.

Roivant and Poxel sign $650M diabetes deal
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 1:53 PM.

Trump pitches changes to 180-day generic exclusivity
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 1:25 PM.

Teva's Copaxone sales hit hastened with OK of Novartis copy
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 12:47 PM.

What Gilead taught pharma about pricing a cure
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 12:11 PM.

New approval helps Vertex's 'cleanest growth story in biotech'
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Tuesday, Feb 13, 2018 at 11:45 AM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 5:59 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 5:26 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 4:58 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 4:25 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 3:10 PM.

Aveo, Eusa tout promise of tivozanib combo in kidney cancer
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 1:50 PM.

Maker of Oxycontin to halt opioid promotion to doctors
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 12:54 PM.

Despite trial win, Roche's new eye drug can't escape Eylea's shadow
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 12, 2018 at 12:25 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 7:03 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 6:34 PM.

SeaGen, Pieris ink deal for bispecific I/O drugs
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 6:05 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 5:32 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 4:59 PM.

Possible migraine drug delay weighs on Teva
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 4:28 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 3:17 PM.

Citing lower tax rate, Amgen plans new biomanufacturing plant
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 2:45 PM.

Madrigal shares slide despite Phase 2 success
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 2:12 PM.

SeaGen, Pieris ink deal for bispecific I/O drugs
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 1:41 PM.

Pharma to pay more under 2-year budget deal
(healthcaredive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 1:09 PM.

Boehringer ends Alzheimer's research for PDE9 blocker
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 12:33 PM.

Possible migraine drug delay weighs on Teva
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 9, 2018 at 12:03 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 8, 2018 at 7:37 PM.

Citing lower tax rate, Amgen plans new biomanufacturing plant
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 8, 2018 at 7:09 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 8, 2018 at 6:40 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 8, 2018 at 6:06 PM.

Alexion turns focus to rebuilding pipeline amid restructuring
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 8, 2018 at 5:36 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 8, 2018 at 5:02 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 6:00 PM.

TG Therapeutics posts positive MS update
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 5:28 PM.

New York latest to sue opioid manufacturer Insys
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 5:00 PM.

Biotech unicorn Intarcia cuts staff and stops trials
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 4:33 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 3:51 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 3:19 PM.

Payers wade into real-world evidence, but tread lightly
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 2:42 PM.

New York latest to sue opioid manufacturer Insys
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 1:34 PM.

Biopharma in charts: Key takeaways from Q4 earnings
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 12:30 PM.

Bristol-Myers talks up lung cancer data
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Monday, Feb 5, 2018 at 11:53 AM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 6:32 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 5:59 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 5:28 PM.

AstraZeneca pins its hopes on China
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 4:53 PM.

Keytruda boosts Merck, yet 2018 will be crucial year
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 4:24 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 2:47 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 2:19 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 1:48 PM.

When real-world evidence becomes a real headache
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 1:12 PM.

Keytruda boosts Merck, yet 2018 will be crucial year
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Friday, Feb 2, 2018 at 11:42 AM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 7:15 PM.

Vical axes CMV vaccine and half its staff in bid to stay afloat
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 6:38 PM.

BioPharma Dive on Twitter
(twitter.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 6:06 PM.

Vertex looks to own CF market before shifting focus
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 5:30 PM.

With biosimilar impact built in, Roche looks to new drugs
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 5:00 PM.

Pfizer's manufacturing fix clears path for Momenta's Copaxone generic
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 4:25 PM.

How Bristol-Myers and Pfizer are using real-world data to unseat warfarin
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 2:38 PM.

Vical axes CMV vaccine and half its staff in bid to stay afloat
(biopharmadive.com)
Tweeted out by BioPharma Dive, @BioPharmaDive, on Thursday, Feb 1, 2018 at 1:44 PM.

© Serendeputy 2011-2017. Email: jason / serendeputy.com